MedTrace Logo

Blood Samples to Identify Biomarkers of Busulfan

NCT02291965 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 139

Last updated 2025-03-03

No results posted yet for this study

Summary

Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance.

Specific Aim 2: To characterize IV BU metabolism by metabolomics.

Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.

Conditions

Sponsors & Collaborators

  • University of Washington

    collaborator OTHER

  • Seattle Children's Hospital

    collaborator OTHER

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Jeannine S. McCune, PharmD · University of Washington

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2019-04-20
Completion
2024-10-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02291965 on ClinicalTrials.gov